<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7306893\results\search\disease\results.xml">
  <result pre="shocked by the first pandemic of the 21st century, the" exact="Severe" post="Acute Respiratory Syndrome Coronavirus (SARS-CoV), resulting in 774 deaths"/>
  <result pre="by the first pandemic of the 21st century, the Severe" exact="Acute" post="Respiratory Syndrome Coronavirus (SARS-CoV), resulting in 774 deaths and"/>
  <result pre="the first pandemic of the 21st century, the Severe Acute" exact="Respiratory" post="Syndrome Coronavirus (SARS-CoV), resulting in 774 deaths and more"/>
  <result pre="first pandemic of the 21st century, the Severe Acute Respiratory" exact="Syndrome" post="Coronavirus (SARS-CoV), resulting in 774 deaths and more than"/>
  <result pre="strain of CoV had evolved that caused the Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV), approximately 2500 cases have been confirmed,"/>
  <result pre="of CoV had evolved that caused the Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV), approximately 2500 cases have been confirmed, including"/>
  <result pre="rate of 34.4%Â [10]. In December 2019, a series of" exact="acute" post="respiratory illness cases with unknown etiology has been reported"/>
  <result pre="of 34.4%Â [10]. In December 2019, a series of acute" exact="respiratory" post="illness cases with unknown etiology has been reported in"/>
  <result pre="was a novel coronavirus and officially named it the coronavirus" exact="disease" post="2019 COVID-19, and the virus was scientifically named SARS-CoV-2,"/>
  <result pre="worst scenarios are possible. Human-to-human transmission of SARS-CoV-2 act through" exact="respiratory" post="droplets and direct contact, though fecal-oral transmission might be"/>
  <result pre="and malaise. Later on, symptoms such as dyspnea, vomiting, and" exact="diarrhea" post="tend to appear. Moreover, the virus was characterized by"/>
  <result pre="suggests that SARS-CoV-2 (similar to SARS-CoV) primarily infects ciliated bronchial" exact="epithelial" post="cells and type II pneumocytes, where it binds to"/>
  <result pre="(similar to SARS-CoV) primarily infects ciliated bronchial epithelial cells and" exact="type II" post="pneumocytes, where it binds to the surface receptor, angiotensin-convertingg"/>
  <result pre="overview of PI and its success in using it for" exact="viral infection" post="treatment and discuss why PI might be a vital"/>
  <result pre="of PI and its success in using it for viral" exact="infection" post="treatment and discuss why PI might be a vital"/>
  <result pre="PI is a method to obtain instant, short-term fortification against" exact="infectious" post="agents by introducing the pathogen-specific antibodies to patients. These"/>
  <result pre="cell receptor, which is extremely applicable in the case of" exact="viral" post="antigens that facilitate the attachment to the target receptorsÂ"/>
  <result pre="attachment to the target receptorsÂ [17]. After exposure to a" exact="viral infection," post="the body of the patient creates antibodies to fight"/>
  <result pre="tested for antibody activity and neutralization activity. In a resource" exact="limited" post="situation, ELISA IgG could be a substitute for neutralization"/>
  <result pre="had been implemented, and patients who received a serum had" exact="lower" post="mortality than othersÂ [13]. Successful experimental usage of PI"/>
  <result pre="donated by five convalescent patients. The mortality rate was significantly" exact="lower" post="(12.5%) than the case fatality rate (80%) in Kikwit"/>
  <result pre="efficacy of CP for the treatment of the Ebola virus" exact="disease" post="(EVD) was carried out in Guinea. Results revealed that"/>
  <result pre="of CPÂ [6]. Moreover, PI has been used against the" exact="chikungunya" post="virus (CHIKV) as well. This is a reemerged arbovirus"/>
  <result pre="is a reemerged arbovirus responsible for a massive outbreak of" exact="infections" post="in India and has a vast potential to spread"/>
  <result pre="the potential of using PI in the treatment of different" exact="viral" post="infections. 4. Passive immunization and coronaviruses Before COVID-19, there"/>
  <result pre="the CP group had a significantly shorter hospital stay and" exact="lower" post="mortality rate than other groupsÂ [18]. This distinction is"/>
  <result pre="in the 21st century and might be the most important" exact="infectious disease" post="that represents a major public health threat to all"/>
  <result pre="the 21st century and might be the most important infectious" exact="disease" post="that represents a major public health threat to all"/>
  <result pre="its discovery, PI has proven to be lifesaving for many" exact="acute" post="infections. Even though COVID-19 might be different, PI experiences"/>
  <result pre="humanity now confronts this pandemic. Different analyses demonstrated that the" exact="viral" post="load and mortality rate were significantly reduced by using"/>
  <result pre="patients in Hong Kong. European Journal of Clinical Microbiology and" exact="Infectious" post="Diseases. 2005. doi:10.1007/s10096-004-1271-9. [3]CoudercT, KhandoudiN, GrandadamM, VisseC, GangneuxN, BagotS,"/>
  <result pre="GrandadamM, VisseC, GangneuxN, BagotS, ProstJ-F, LecuitM. Prophylaxis and therapy for" exact="chikungunya" post="virus infection. The Journal of Infectious Diseases. 2009. doi:10.1086/600381."/>
  <result pre="VisseC, GangneuxN, BagotS, ProstJ-F, LecuitM. Prophylaxis and therapy for chikungunya" exact="virus infection." post="The Journal of Infectious Diseases. 2009. doi:10.1086/600381. [4]GeXY, LiJL,"/>
  <result pre="Prophylaxis and therapy for chikungunya virus infection. The Journal of" exact="Infectious" post="Diseases. 2009. doi:10.1086/600381. [4]GeXY, LiJL, YangXL, ChmuraAA, ZhuG, EpsteinJH,"/>
  <result pre="influenza A(H1N1) pneumonitis and immunoglobulin G2 subclass (IgG2) deficiency. Clinical" exact="Infectious" post="Diseases. 2011. doi:10.1093/cid/ciq082. [6]GriensvenJV, EdwardsT, De LamballerieX, SempleMG, GallianP,"/>
  <result pre="GallianP, BaizeS, HorbyPWet al.Evaluation of convalescent plasma for ebola virus" exact="disease" post="in Guinea. New England Journal of Medicine. 2016. doi:10.1056/NEJMoa1511812."/>
  <result pre="LiangW-h, OuC-q, HeJ-x, LiuLet al.Clinical characteristics of 2019 novel coronavirus" exact="infection" post="in China. New England Journal of Medicine. 2020. doi:10.1101/2020.02.06.20020974."/>
  <result pre="SchoemanMC, DrostenC, DrexlerJF, PreiserW. Close relative of human middle east" exact="respiratory" post="syndrome coronavirus in bat, South Africa. Emerging Infectious Diseases."/>
  <result pre="DrostenC, DrexlerJF, PreiserW. Close relative of human middle east respiratory" exact="syndrome" post="coronavirus in bat, South Africa. Emerging Infectious Diseases. 2013."/>
  <result pre="middle east respiratory syndrome coronavirus in bat, South Africa. Emerging" exact="Infectious" post="Diseases. 2013. doi:10.3201/eid1910.130946. [11]KoJH, HyeriS, ChoSY, HaYE, BaekJY, KimSH,"/>
  <result pre="KimYJet al.Challenges of convalescent plasma infusion therapy in middle east" exact="respiratory" post="coronavirus infection: A single centre experience. Antiviral Therapy. 2018."/>
  <result pre="GrazziniG. Convalescent plasma: New evidence for an old therapeutic tool?." exact="Blood" post="Transfusion. 2016. doi:10.2450/2015.0131-15. [15]MupapaK, MassambaM, KibadiK, KuvulaK, BwakaA, KipasaM,"/>
  <result pre="fever with blood transfusions from convalescent patients. The Journal of" exact="Infectious" post="Diseases. 1999. doi:10.1086/514298. [16]QinE, HuiyingS, LinT, CuieW, ChangG, DingZ,"/>
  <result pre="CarloneGM, AdesEW. An augmented passive immune therapy to treat fulminant" exact="bacterial infections." post="Recent Patents on Anti-Infective Drug Discovery. 2010. doi:10.2174/157489110791233496. [18]SooYOY,"/>
  <result pre="ZhangS, FieldH, DaszakP, EatonBT. Review of bats and SARS. Emerging" exact="Infectious" post="Diseases. 2006. doi:10.3201/eid1212.060401. [20]YehKM, ChiuehTS, SiuLK, LinJC, ChanPKS, PengMY,"/>
  <result pre="ChanPKS, PengMY, WanHLet al.Experience of using convalescent plasma for severe" exact="acute" post="respiratory syndrome among healthcare workers in a Taiwan hospital."/>
  <result pre="PengMY, WanHLet al.Experience of using convalescent plasma for severe acute" exact="respiratory" post="syndrome among healthcare workers in a Taiwan hospital. Journal"/>
  <result pre="WanHLet al.Experience of using convalescent plasma for severe acute respiratory" exact="syndrome" post="among healthcare workers in a Taiwan hospital. Journal of"/>
 </snippets>
</snippetsTree>
